People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ambrx Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
John W. Wallen, III at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John W. Wallen, III on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David B Singer | 1 | 5 |
| John D. Diekman | 1 | 4 |
| Peter G. Schultz | 1 | 3 |
| Stephen W. Kaldor | 1 | 3 |
| Allan Marchington | 1 | 3 |
| Shehan Dissanayake | 1 | 2 |
| Richard D. DiMarchi | 1 | 1 |
| Douglas W. Axelrod | 1 | 1 |
| Crispina Calsada | 1 | 1 |
| Ho Sung Cho | 1 | 1 |
| August M. Watanabe | 1 | 1 |
| Kevin L. Eastwood | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.